Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03533127
Other study ID # LY01008
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date November 27, 2017
Est. completion date December 28, 2020

Study information

Verified date July 2018
Source Luye Pharma Group Ltd.
Contact Can Wu
Phone 13811253790
Email wucan@luye.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Randomized, Double-blind, Multicenter Phase III Study Comparing Efficacy and Safety of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth Factor Monoclonal Antibody Injection) and Bevacizumab Combined with Paclitaxel and Carboplatin for Treatment of Naïve Subjects with Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer


Description:

The objectives are to compare the efficacy, safety and immunogenicity of LY01008 and bevacizumab combined with paclitaxel and carboplatin for treatment of subjects with metastatic or recurrent nonsquamous non-small cell lung cancer.

The subjects will receive the treatment with LY01008 or bevacizumab combined with paclitaxel and carboplatin for 4-6 cycles, and then both groups of subjects will receive the maintenance monotherapy with LY01008 until occurrence of progressive disease (PD), intolerable toxicity reaction, withdrawal of informed consent, loss to follow-up, death, conduct of other antineoplastic therapy or completion of the whole study. The doses of LY01008 and bevacizumab are 15 mg/kg in combination therapy. The dose of LY01008 in maintenance monotherapy is 15 mg/kg.


Recruitment information / eligibility

Status Recruiting
Enrollment 648
Est. completion date December 28, 2020
Est. primary completion date June 28, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- The subject has voluntarily signed the written informed consent form (ICF)

- Male or female patients aged 18 to 75 years (18 years and 75 years are inclusive)

- The patients with metastatic (stage IV) or recurrent nonsquamous NSCLC proved by histological or cytological demonstrated who cannot have surgical treatment. The diagnosis result of nonsquamous NSCLC obtained only based on the sputum cytology is not accepted. If the patient has many kinds of tumor components, the main cell types should be classified;

- The patient should have at least one measurable lesion as the target lesion (according to RECIST 1.1 criteria);

- The Eastern Cooperative Oncology Group (ECOG) performance status score is 0 to 1 point.

- The predictable survival duration is = 6 months

- Laboratory results during screening:

- Blood routine: white blood cell count = 3.0× 109/L, absolute neutrophil count = 1.5× 109/L, platelet count= 100× 109/L and hemoglobin= 90 g/L.

- Liver function: Total bilirubin <1.5×upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5×ULN for the subjects without liver metastasis and ALT and AST< 5×ULN for the subjects with liver metastasis.

- Kidney function: Serum creatinine = 1.5 ×ULN or creatinine clearance rate = 50 mL/min and urine protein <2+ ( quantitative test for 24h urine protein should be conducted when the baseline urine protein is 2+ and the subject can only be enrolled when the 24 h urine protein quantitation is = 1 g );

- The international normalized ratio (INR) = 1.5 and partial thromboplastin time (PTT or aPTT) = 1.5 × ULN within 7 days before the study treatment

- The subject can comply with the study protocol.

- The female subjects and male subjects of childbearing age and the partners of the male subjects agree to take reliable contraceptive measures (such as abstinence, sterilizing operation, contraceptives, injection of the contraceptive drug medroxyprogesterone acetate or subdermal implant of contraceptives

Exclusion Criteria:

- The patients who have received chemotherapy or other systemic antineoplastic therapy drugs (such monoclonal antibodies and tyrosine kinase inhibitors) for the disease of the current stage (stage IV or recurrent disease). The patients are allowed to have received past surgery and radiotherapy, but they must meet the criteria for the related two treatment methods listed in the study protocol. The subjects who have recurrented after adjuvant/ neoadjuvant chemotherapy can also be enrolled if the interval between the completion time of the adjuvant/ neoadjuvant therapy and the administration time of the initial dose of the study is more than 6 months;

- The subjects with mixed NSCLC which containing small cell cancer component or the squamous-cell carcinoma component dominant;

- The patient has history of hemoptysis within 3 months before screening and the expectorated fresh blood is = 2.5 mL.

- The images reveal sign of tumor invasion in great vessels. The subjects with tumor completely closes to, surrounds or invades the lumen of great vessels (such as pulmonary artery or superior vena cava) must be excluded;

- The subjects with symptomatic brain metastasis, a history of spinal cord compression or meningeal metastases and subjects who have previously received brain metastasis treatment, if their lesion is radiographically confirmed to have remained stable for more than 4 weeks at screening, can be enrolled;

- The subjects who have received radical thoracic radiotherapy within 28 days before enrollment and the subjects who have received palliative radiotherapy for the bone lesions besides chest within 2 weeks before the treatment with the first dose of study drugs;

- The subjects who have had major surgery, major trauma (such as fracture) within 28 days before randomization or the subjects who are expected to have major surgery during the study cycle ;

- The patients who are taking or have taken aspirin (>325 mg/day) or other non-steroidal anti-inflammatory drugs which are known to be able to inhibit platelet function recently (within 10 days before receiving the initial dose of the study drugs);

- The patients who are taking or have taken whole dose oral or parenteral anticoagulation drugs or thrombolytic agents recently (within 10 days before receiving the initial dose of the study drugs). However, the patients are allowed to have preventive use of anticoagulation drugs;

- The patients who have inherited bleeding tendency or coagulation disorders;

- The patient with thrombotic diseases which revealed by medical history or examination results within 6 months before enrollment;

- The patient with uncontrolled hypertension (systolic pressure is more than 150 mmHg and/or diastolic pressure is more than 100 mmHg), hypertensive crisis or history of hypertensive encephalopathy;

- The patient with any unstable systemic disease: including but not limited to unstable angina pectoris, cerebrovascular accident or transient cerebral ischemia (within 6 months before screening), myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification = grade II), serious arrhythmia,liver, kidney or metabolic diseases that need drug treatment,

- The patient with serious unhealed wound and gastrointestinal ulcer. Medical history of the following diseases within 6 months before screening: gastrointestinal perforation, corrosive esophagitis or gastritis, inflammatory bowel disease or diverticulitis, abdominal fistula or intra-abdominal abscess.

- The patient with tracheo-esophageal fistula;

- The patient with malignant tumors except NSCLC within 5 years before randomization, except the sufficiently treated carcinoma in situ of cervix, basal cell carcinoma or squamous epithelial cancer, local prostate cancer after radical operation, ductal carcinoma in situ after radical operation

- The patient with medical history of peripheral neuropathy;

- The patient with persistent or active infection signs which need intravenous injection of antibiotics, neurological or metabolic dysfunction, contraindications of the study drugs appear in the physical examination results or laboratory examination results or the patients have signs of suspected diseases or symptoms which result in that the patient has high risk for the treatment related complications;

- The patient with hepatitis B surface antigen (HBsAg) positive and the peripheral blood HBV DNA titer =1× 103 copies/mL. The subject is eligible to be enrolled if HBsAg is positive and peripheral blood HBV DNA titer <1×103 copies/mL and the investigator considers that the subject is at the stable stage of chronic hepatitis and the risk will not be increased for the subject;

- The patient with hepatitis C virus (HCV) antibody and human immunodeficiency virus (HIV) antibody positive.

- The patient has received treatment with any other investigational drugs or has participated in another interventional clinical trial within 30 days before screening

- The patient with known allergy to bevacizumab or its any excipient or paclitaxel and carboplatin drug components

- The patient has bibulosity within 1 month prior to screening (ie, drinking more than 14 units of alcohol per week (1 unit=360 mL of beer or 45 ml of 40% liquor or 150 mL of wine) or a history of drug abuse;

- Pregnant or lactating women or women who prepare to be pregnant or lactate during the study period.

- Other circumstances which are considered by the investigator that the subject is unsuitable to be enrolled

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LY01008
LY01008+Carboplatin/Paclitaxel
Bevacizumab
Bevacizumab + Carboplatin/Paclitaxel

Locations

Country Name City State
China Chinese Academy of Medical Sciences Chaoyang Beijing

Sponsors (1)

Lead Sponsor Collaborator
Luye Pharma Group Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Best Objective Response Rate 19 weeks from randomization
Secondary Progression Free Survival from the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject
Secondary Overall Survival from the date of randomisation to the date of death up to 12 months from randomisation of the last subject
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Completed NCT01945021 - Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Phase 2
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Terminated NCT04022876 - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Phase 1
Recruiting NCT05898763 - TEIPP Immunotherapy in Patients With NSCLC Phase 1/Phase 2
Recruiting NCT05532696 - Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients Phase 1/Phase 2
Completed NCT04311034 - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Completed NCT00349089 - Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04571632 - Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors Phase 2
Terminated NCT03599518 - DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06020989 - Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy Phase 2
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1
Withdrawn NCT03574649 - QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02844140 - DE-CT in Lung Cancer Proton Therapy N/A
Completed NCT03780010 - Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC Phase 1